Relevance of neo- or adjuvant pretreatment in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab as first-line treatment – data from the prospective TKK registry.

Schnell, R., Trarbach, T., Broszeit-Luft, S., Musch, R., Wetzel, N., Kopfmann, S., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V395), 114. doi:10.1159/000439070

Studie: TKK; Indikation: Kolorektalkarzinom; Jahr: 2015; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com